Cargando…
Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
Rheumatoid arthritis (RA) is associated with systemic osteoporosis, which leads to severe disability and low quality of life. Current therapies target osteoclasts to reduce bone degradation, but more treatment options would be required to promote bone protection by acting directly on osteoblasts (OB...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140103/ https://www.ncbi.nlm.nih.gov/pubmed/35626646 http://dx.doi.org/10.3390/cells11101609 |
_version_ | 1784715017218686976 |
---|---|
author | Schwendich, Elena Salinas Tejedor, Laura Schmitz, Gernot Rickert, Markus Steinmeyer, Jürgen Rehart, Stefan Tsiami, Styliani Braun, Jürgen Baraliakos, Xenofon Reinders, Jörg Neumann, Elena Müller-Ladner, Ulf Capellino, Silvia |
author_facet | Schwendich, Elena Salinas Tejedor, Laura Schmitz, Gernot Rickert, Markus Steinmeyer, Jürgen Rehart, Stefan Tsiami, Styliani Braun, Jürgen Baraliakos, Xenofon Reinders, Jörg Neumann, Elena Müller-Ladner, Ulf Capellino, Silvia |
author_sort | Schwendich, Elena |
collection | PubMed |
description | Rheumatoid arthritis (RA) is associated with systemic osteoporosis, which leads to severe disability and low quality of life. Current therapies target osteoclasts to reduce bone degradation, but more treatment options would be required to promote bone protection by acting directly on osteoblasts (OB). Recently, the local production of dopamine in inflamed joints of RA has been observed. Thus, in this project, we aimed to determine the implication of the neurotransmitter dopamine in the bone formation process in RA. Dopamine receptors (DR) in the human bone tissue of RA or osteoarthritis (OA) patients were examined by immunohistochemistry. DR in isolated human osteoblasts (OB) was analyzed by flow cytometry, and dopamine content was evaluated by ELISA. Osteoclasts (OC) were differentiated from the PBMCs of healthy controls (HC) and RA patients. Isolated cells were treated with specific dopamine agonists. The effect of dopamine on mineralization was evaluated by Alizarin red staining. Cytokine release in supernatants was measured by ELISA. Osteoclastogenesis was evaluated with TRAP staining. OC markers were analyzed via real-time PCR and bone resorption via staining of resorption pits with toluidine blue. All DR were observed in bone tissue, especially in the bone remodeling area. Isolated OB maintained DR expression, which allowed their study in vitro. Isolated OB expressed tyrosine hydroxylase, the rate-limiting enzyme for dopamine production, and contained dopamine. The activation of D2-like DR significantly increased bone mineralization in RA osteoblasts and increased osteoclastogenesis but did not alter the expression of OC markers nor bone resorption. DR were found in the bone remodeling area of human bone tissue and dopamine can be produced by osteoblasts themselves, thus suggesting a local autocrine/paracrine pathway of dopamine in the bone. D2-like DRs are responsible for bone mineralization in osteoblasts from RA patients without an increase in bone resorption, thus suggesting the D2-like DR pathway as a possible future therapeutic target to counteract bone resorption in arthritis. |
format | Online Article Text |
id | pubmed-9140103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91401032022-05-28 Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis Schwendich, Elena Salinas Tejedor, Laura Schmitz, Gernot Rickert, Markus Steinmeyer, Jürgen Rehart, Stefan Tsiami, Styliani Braun, Jürgen Baraliakos, Xenofon Reinders, Jörg Neumann, Elena Müller-Ladner, Ulf Capellino, Silvia Cells Article Rheumatoid arthritis (RA) is associated with systemic osteoporosis, which leads to severe disability and low quality of life. Current therapies target osteoclasts to reduce bone degradation, but more treatment options would be required to promote bone protection by acting directly on osteoblasts (OB). Recently, the local production of dopamine in inflamed joints of RA has been observed. Thus, in this project, we aimed to determine the implication of the neurotransmitter dopamine in the bone formation process in RA. Dopamine receptors (DR) in the human bone tissue of RA or osteoarthritis (OA) patients were examined by immunohistochemistry. DR in isolated human osteoblasts (OB) was analyzed by flow cytometry, and dopamine content was evaluated by ELISA. Osteoclasts (OC) were differentiated from the PBMCs of healthy controls (HC) and RA patients. Isolated cells were treated with specific dopamine agonists. The effect of dopamine on mineralization was evaluated by Alizarin red staining. Cytokine release in supernatants was measured by ELISA. Osteoclastogenesis was evaluated with TRAP staining. OC markers were analyzed via real-time PCR and bone resorption via staining of resorption pits with toluidine blue. All DR were observed in bone tissue, especially in the bone remodeling area. Isolated OB maintained DR expression, which allowed their study in vitro. Isolated OB expressed tyrosine hydroxylase, the rate-limiting enzyme for dopamine production, and contained dopamine. The activation of D2-like DR significantly increased bone mineralization in RA osteoblasts and increased osteoclastogenesis but did not alter the expression of OC markers nor bone resorption. DR were found in the bone remodeling area of human bone tissue and dopamine can be produced by osteoblasts themselves, thus suggesting a local autocrine/paracrine pathway of dopamine in the bone. D2-like DRs are responsible for bone mineralization in osteoblasts from RA patients without an increase in bone resorption, thus suggesting the D2-like DR pathway as a possible future therapeutic target to counteract bone resorption in arthritis. MDPI 2022-05-11 /pmc/articles/PMC9140103/ /pubmed/35626646 http://dx.doi.org/10.3390/cells11101609 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schwendich, Elena Salinas Tejedor, Laura Schmitz, Gernot Rickert, Markus Steinmeyer, Jürgen Rehart, Stefan Tsiami, Styliani Braun, Jürgen Baraliakos, Xenofon Reinders, Jörg Neumann, Elena Müller-Ladner, Ulf Capellino, Silvia Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis |
title | Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis |
title_full | Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis |
title_fullStr | Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis |
title_full_unstemmed | Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis |
title_short | Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis |
title_sort | modulation of dopamine receptors on osteoblasts as a possible therapeutic strategy for inducing bone formation in arthritis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140103/ https://www.ncbi.nlm.nih.gov/pubmed/35626646 http://dx.doi.org/10.3390/cells11101609 |
work_keys_str_mv | AT schwendichelena modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT salinastejedorlaura modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT schmitzgernot modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT rickertmarkus modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT steinmeyerjurgen modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT rehartstefan modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT tsiamistyliani modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT braunjurgen modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT baraliakosxenofon modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT reindersjorg modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT neumannelena modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT mullerladnerulf modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis AT capellinosilvia modulationofdopaminereceptorsonosteoblastsasapossibletherapeuticstrategyforinducingboneformationinarthritis |